TY - JOUR T1 - May we overcome the current serious limitations for distributing reconstituted mRNA vaccines? JF - medRxiv DO - 10.1101/2021.03.09.21253129 SP - 2021.03.09.21253129 AU - Santiago Grau AU - Olivia Ferrández AU - Elena Martín-García AU - Rafael Maldonado Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.03.09.21253129.abstract N2 - There is an urgent need to ameliorate the transport of the reconstituted vaccines to the vaccination sites to improve the COVID-19 vaccination campaigns. The maintenance of the integrity of the mRNA of the different COVID-19 reconstituted vaccines after continuous movement at room temperature during at least three hours ensures the safety of a ground transportation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was recieved.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not aplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available. ER -